person · Reporting owner

HURWITZ EDWARD

Disclosed activity across 4 companies

Tapewire entity: 40092
SEC CIK: 0001211840

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Dyne Therapeutics, Inc.DYN · Entity 3948	Director	June 05, 2026	June 09, 2026
MACROGENICS INCMGNX · Entity 6104	Director	May 18, 2026	May 20, 2026
TURMERIC ACQUISITION CORP.TMPM · Entity 139875	Chief Financial Officer	October 15, 2020	October 15, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dyne Therapeutics, Inc.

Report date June 05, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.04 · Expires 2036-06-04	Direct	35,152	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 35,152 · Balance 35,152 F1: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

MACROGENICS INC

Report date May 18, 2026 · Filed May 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	47,824	Reported balance After 2026-05-18 transaction · row 1 1 source row Row 1 · 2026-05-18 · Exercise / conversion · Acquired 3,750 · Balance 47,824 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-05-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-18 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	3,750	Reported balance After 2026-05-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19	Direct	22,000	Reported balance After 2026-05-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.

F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

TURMERIC ACQUISITION CORP.

Report date October 15, 2020 · Filed October 15, 2020

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

APPLIED GENETIC TECHNOLOGIES CORP

Report date November 30, 2022 · Filed December 01, 2022

Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-11-30 transaction · row 1 1 source row Row 1 · 2022-11-30 · Other · Disposed 25,672 · Balance 0 F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.
Common StockSEC Table I · non-derivative	IndirectBy Hurwitz/Lichtenfeld Revocable Trust	Reported balance After 2022-11-30 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-11-30 · Other · Disposed 1,800 · Balance 0 F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2024-03-26	Direct	Reported balance After 2022-11-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-30 · Disposition to issuer · Disposed 9,375 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.83 · Expires 2024-12-19	Direct	Reported balance After 2022-11-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-30 · Disposition to issuer · Disposed 4,688 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.06 · Expires 2025-11-19	Direct	Reported balance After 2022-11-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-11-30 · Disposition to issuer · Disposed 6,200 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.75 · Expires 2027-02-28	Direct	Reported balance After 2022-11-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-11-30 · Disposition to issuer · Disposed 8,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2028-07-25	Direct	Reported balance After 2022-11-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2028-11-15	Direct	Reported balance After 2022-11-30 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2029-12-04	Direct	Reported balance After 2022-11-30 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-12-16	Direct	Reported balance After 2022-11-30 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-11-30 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2031-11-30	Direct	Reported balance After 2022-11-30 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-11-30 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.

Filing footnotes · ownership attribution and instrument terms

F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 9, 2026 21:15 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock option (right to buy) · Derivative	35,152	$0.00 Strike: $17.04	$0.00	Disclosure SEC source: 0001193125-26-264031 · ownership.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,152 Underlying: Common Stock · 35,152 shares Expires 2036-06-04 F1 · derivative.exercise_date: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document
May 19, 2026 Filed May 20, 2026 20:13 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	22,000	$0.00 Strike: $4.52	$0.00	Disclosure SEC source: 0001211840-26-000002 · wk-form4_1779308015.xml · derivative · entry 4 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-19 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
May 19, 2026 Filed May 20, 2026 20:13 UTC	MACROGENICS INC MGNX · Entity 6104	GrantRestricted Stock Unit · Derivative	3,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001211840-26-000002 · wk-form4_1779308015.xml · derivative · entry 3 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document
May 18, 2026 Filed May 20, 2026 20:13 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionRestricted Stock Unit · Derivative	3,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001211840-26-000002 · wk-form4_1779308015.xml · derivative · entry 2 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. F2 · derivative.expiration_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. Read SEC document
May 18, 2026 Filed May 20, 2026 20:13 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionCommon Stock	3,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001211840-26-000002 · wk-form4_1779308015.xml · nonDerivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 30, 2025 Filed Jun 4, 2025 01:41 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock option (right to buy) · Derivative	35,000	$0.00 Strike: $11.96	$0.00	Disclosure SEC source: 0000950170-25-081360 · ownership.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. Read SEC document
May 21, 2025 Filed May 22, 2025 20:01 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	22,000	$0.00 Strike: $1.49	$0.00	Disclosure SEC source: 0001125345-25-000078 · wk-form4_1747944109.xml · derivative · entry 4 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-05-21 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
May 21, 2025 Filed May 22, 2025 20:01 UTC	MACROGENICS INC MGNX · Entity 6104	GrantRestricted Stock Unit · Derivative	3,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-25-000078 · wk-form4_1747944109.xml · derivative · entry 3 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document
May 20, 2025 Filed May 22, 2025 20:01 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionRestricted Stock Unit · Derivative	6,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-25-000078 · wk-form4_1747944109.xml · derivative · entry 2 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. F2 · derivative.expiration_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. Read SEC document
May 20, 2025 Filed May 22, 2025 20:01 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionCommon Stock	6,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001125345-25-000078 · wk-form4_1747944109.xml · nonDerivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 22, 2024 Filed May 24, 2024 21:10 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock option (right to buy) · Derivative	25,133	$0.00 Strike: $31.53	$0.00	Disclosure SEC source: 0000950170-24-064726 · ownership.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,133 Underlying: Common Stock · 25,133 shares Expires 2034-05-21 F1 · derivative.exercise_date: This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service. Read SEC document
May 21, 2024 Filed May 23, 2024 21:16 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	16,500	$0.00 Strike: $4.26	$0.00	Disclosure SEC source: 0001125345-24-000127 · wk-form4_1716498965.xml · derivative · entry 2 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-21 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
May 21, 2024 Filed May 23, 2024 21:16 UTC	MACROGENICS INC MGNX · Entity 6104	GrantRestricted Stock Unit · Derivative	6,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-24-000127 · wk-form4_1716498965.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document
May 20, 2024 Filed May 22, 2024 20:32 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionRestricted Stock Unit · Derivative	4,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-24-000101 · wk-form4_1716409937.xml · derivative · entry 2 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. F2 · derivative.expiration_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. Read SEC document
May 20, 2024 Filed May 22, 2024 20:32 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001125345-24-000101 · wk-form4_1716409937.xml · nonDerivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. Read SEC document
August 30, 2023 Filed Sep 1, 2023 20:06 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	15,000	$4.91	$73,650.00	Disclosure SEC source: 0001125345-23-000111 · wk-form4_1693598784.xml · nonDerivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,074 F1 · price: The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.90 to $4.91. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:58 UTC	MACROGENICS INC MGNX · Entity 6104	GrantRestricted Stock Unit · Derivative	4,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-23-000099 · wk-form4_1685739483.xml · derivative · entry 2 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:58 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	19,000	$0.00 Strike: $4.67	$0.00	Disclosure SEC source: 0001125345-23-000099 · wk-form4_1685739483.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
May 24, 2023 Filed May 25, 2023 22:36 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock Option (right to buy) · Derivative	24,900	$0.00 Strike: $13.49	$0.00	Disclosure SEC source: 0001209191-23-032274 · doc4.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2033-05-23 F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	14,000	Not disclosed Strike: $2.17	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 11 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2031-11-30 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	12,000	Not disclosed Strike: $4.72	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 10 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-12-16 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $3.02	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 9 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-12-04 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $6.90	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 8 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-11-15 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $4.25	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 7 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-07-25 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	8,000	Not disclosed Strike: $7.75	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 6 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2027-02-28 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	6,200	Not disclosed Strike: $16.06	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 5 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,200 shares Expires 2025-11-19 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	4,688	Not disclosed Strike: $20.83	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 4 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,688 shares Expires 2024-12-19 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	9,375	Not disclosed Strike: $12.00	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · derivative · entry 3 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,375 shares Expires 2024-03-26 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	OtherCommon Stock	1,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · nonDerivative · entry 2 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Hurwitz/Lichtenfeld Revocable Trust Disclosed balance after: 0 F1 · shares: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. F1 · price: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:19 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	OtherCommon Stock	25,672	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-22-023026 · form4.xml · nonDerivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. F1 · price: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. Read SEC document
June 03, 2022 Filed Jun 6, 2022 20:05 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock Option (right to buy) · Derivative	19,596	$0.00 Strike: $4.58	$0.00	Disclosure SEC source: 0001209191-22-034490 · doc4.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,596 Underlying: Common Stock · 19,596 shares Expires 2032-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document
May 19, 2022 Filed May 24, 2022 01:06 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $3.90	$0.00	Disclosure SEC source: 0001125345-22-000064 · wf-form4_165335438800176.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
November 30, 2021 Filed Dec 2, 2021 18:49 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	GrantStock Option (right to buy) · Derivative	14,000	$0.00 Strike: $2.17	$0.00	Disclosure SEC source: 0001062993-21-012053 · form4.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-11-30 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over one year from the date of grant. Read SEC document
May 26, 2021 Filed May 28, 2021 00:38 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock Option (right to buy) · Derivative	19,596	$0.00 Strike: $19.56	$0.00	Disclosure SEC source: 0000899243-21-020988 · doc4.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,596 Underlying: Common Stock · 19,596 shares Expires 2031-05-25 F1 · derivative.exercise_date: This option was granted on May 26, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 26, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders Read SEC document
May 13, 2021 Filed May 18, 2021 01:27 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $28.88	$0.00	Disclosure SEC source: 0001125345-21-000073 · wf-form4_162130122095194.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
December 16, 2020 Filed Dec 18, 2020 17:20 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $4.72	$0.00	Disclosure SEC source: 0001273636-20-000011 · edgar.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over one year from the date of grant. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionSeries B Preferred Stock · Derivative	26,176	$0.00	$0.00	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 15 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 7,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.exercise_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.expiration_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5 · ownership.nature: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionSeries B Preferred Stock · Derivative	70,492	$0.00	$0.00	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 14 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 21,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.exercise_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.expiration_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionSeries B Preferred Stock · Derivative	1,326,313	$0.00	$0.00	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 13 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 399,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.exercise_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.expiration_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionSeries A Preferred Stock · Derivative	275,932	$0.00	$0.00	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 12 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 83,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5 · ownership.nature: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionSeries A Preferred Stock · Derivative	743,076	$0.00	$0.00	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 11 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 224,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionSeries A Preferred Stock · Derivative	13,980,992	$0.00	$0.00	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 10 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 4,215,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionCommon Stock	91,081	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · nonDerivative · entry 3 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 91,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5 · ownership.nature: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionCommon Stock	245,279	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · nonDerivative · entry 2 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 245,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any. Read SEC document
September 21, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionCommon Stock	4,614,943	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · nonDerivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,614,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any. Read SEC document
August 07, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	PurchaseSeries B Preferred Stock · Derivative	26,176	$2.81	$73,580.74	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 9 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 26,176 Underlying: Common Stock · 7,893 shares Expires not disclosed F7 · derivative.exercise_price: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F7 · derivative.exercise_date: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F7 · derivative.expiration_date: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5 · ownership.nature: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any. Read SEC document
August 07, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	PurchaseSeries B Preferred Stock · Derivative	70,492	$2.81	$198,153.01	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 8 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 70,492 Underlying: Common Stock · 21,254 shares Expires not disclosed F7 · derivative.exercise_price: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F7 · derivative.exercise_date: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F7 · derivative.expiration_date: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any. Read SEC document
August 07, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	PurchaseSeries B Preferred Stock · Derivative	1,326,313	$2.81	$3,728,265.84	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 7 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,326,313 Underlying: Common Stock · 399,867 shares Expires not disclosed F7 · derivative.exercise_price: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F7 · derivative.exercise_date: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F7 · derivative.expiration_date: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any. Read SEC document
July 31, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	PurchaseSeries A Preferred Stock · Derivative	96,576	$1.00	$96,576.00	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 6 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 275,932 Underlying: Common Stock · 29,116 shares Expires not disclosed F6 · derivative.exercise_price: The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F6 · derivative.exercise_date: The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F6 · derivative.expiration_date: The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5 · ownership.nature: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any. Read SEC document
July 31, 2020 Filed Sep 23, 2020 22:55 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	PurchaseSeries A Preferred Stock · Derivative	260,077	$1.00	$260,077.00	Disclosure SEC source: 0000899243-20-026170 · doc4.xml · derivative · entry 5 HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 743,076 Underlying: Common Stock · 78,409 shares Expires not disclosed F6 · derivative.exercise_price: The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F6 · derivative.exercise_date: The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F6 · derivative.expiration_date: The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.